GW Pharmaceuticals (LON:GWP) - Fourth partner secured

Tuesday, Apr 12 2011 by

Apr 12th 2011 - Edison Investment Research today published a report on GW Pharmaceuticals (GWP.L, LSE:GWP, LON:GWP) entitled "Fourth Partner Secured". In summary, the report says:

Novartis has become the fourth Sativex partner as GW’s global commercialisation efforts gather momentum. Under the terms of this latest licensing deal, Novartis has gained exclusive commercialisations rights, with responsibility for regulatory filings, in Australia, New Zealand, Asia (ex-Japan, China and HK), the Middle East (ex-Israel/ Palestine) and Africa. This deal provides further large pharma validation for Sativex, with GW benefiting from Novartis’s broad geographic presence and strong multiple sclerosis and cancer franchise. Terms include $5m upfront and $28m of milestones.




About Edison Investment Research

Edison Investment Research

Follow

Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »


 
Join us at the London Investor Show next Friday at Olympia